Kavita V Dharmarajan1, Debra L Friedman2, T J FitzGerald3, Kathleen M McCarten4, Louis S Constine5, Lu Chen6, Sandy K Kessel3, Matt Iandoli3, Fran Laurie3, Cindy L Schwartz7, Suzanne L Wolden8. 1. Mount Sinai Medical Center, New York, New York. 2. Vanderbilt University, Nashville, Tennessee. 3. Quality Assurance Review Center, Lincoln, Rhode Island. 4. Rhode Island Hospital/Warren Alpert Medical School of Brown University, Providence, Rhode Island. 5. University of Rochester Medical Center, Rochester, New York. 6. Children's Oncology Group, Arcadia, California. 7. MD Anderson Cancer Center, Houston, Texas. 8. Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: A phase 3 trial assessing response-based therapy in intermediate-risk Hodgkin lymphoma mandated real-time central review of involved field radiation therapy (IFRT) and imaging records by a centralized review center to maximize protocol compliance. We report the impact of centralized radiation therapy review on protocol compliance. METHODS AND MATERIALS: Review of simulation films, port films, and dosimetry records was required before and after treatment. Records were reviewed by study-affiliated or review center-affiliated radiation oncologists. A deviation of 6% to 10% from protocol-specified dose was scored as "minor"; a deviation of >10% was "major." A volume deviation was scored as "minor" if margins were less than specified or "major" if fields transected disease-bearing areas. Interventional review and final compliance review scores were assigned to each radiation therapy case and compared. RESULTS: Of 1712 patients enrolled, 1173 underwent IFRT at 256 institutions in 7 countries. An interventional review was performed in 88% of patients and a final review in 98%. Overall, minor and major deviations were found in 12% and 6% of patients, respectively. Among the cases for which ≥1 pre-IFRT modification was requested by the Quality Assurance Review Center and subsequently made by the treating institution, 100% were made compliant on final review. By contrast, among the cases for which ≥1 modification was requested but not made by the treating institution, 10% were deemed compliant on final review. CONCLUSIONS: In a large trial with complex treatment pathways and heterogeneous radiation therapy fields, central review was performed in a large percentage of cases before IFRT and identified frequent potential deviations in a timely manner. When suggested modifications were performed by the institutions, deviations were almost eliminated.
RCT Entities:
PURPOSE: A phase 3 trial assessing response-based therapy in intermediate-risk Hodgkin lymphoma mandated real-time central review of involved field radiation therapy (IFRT) and imaging records by a centralized review center to maximize protocol compliance. We report the impact of centralized radiation therapy review on protocol compliance. METHODS AND MATERIALS: Review of simulation films, port films, and dosimetry records was required before and after treatment. Records were reviewed by study-affiliated or review center-affiliated radiation oncologists. A deviation of 6% to 10% from protocol-specified dose was scored as "minor"; a deviation of >10% was "major." A volume deviation was scored as "minor" if margins were less than specified or "major" if fields transected disease-bearing areas. Interventional review and final compliance review scores were assigned to each radiation therapy case and compared. RESULTS: Of 1712 patients enrolled, 1173 underwent IFRT at 256 institutions in 7 countries. An interventional review was performed in 88% of patients and a final review in 98%. Overall, minor and major deviations were found in 12% and 6% of patients, respectively. Among the cases for which ≥1 pre-IFRT modification was requested by the Quality Assurance Review Center and subsequently made by the treating institution, 100% were made compliant on final review. By contrast, among the cases for which ≥1 modification was requested but not made by the treating institution, 10% were deemed compliant on final review. CONCLUSIONS: In a large trial with complex treatment pathways and heterogeneous radiation therapy fields, central review was performed in a large percentage of cases before IFRT and identified frequent potential deviations in a timely manner. When suggested modifications were performed by the institutions, deviations were almost eliminated.
Authors: Lynn Million; James Anderson; John Breneman; Douglas S Hawkins; Fran Laurie; Jeff Michalski; David Rodeberg; Moody Wharam; Suzanne Wolden; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-18 Impact factor: 7.038
Authors: M A Weiner; B Leventhal; M L Brecher; R B Marcus; A Cantor; P W Gieser; J L Ternberg; F G Behm; M D Wharam; A R Chauvenet Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: Thomas J Fitzgerald; Maryann Bishop-Jodoin; M Giulia Cicchetti; Richard Hanusik; Sandy Kessel; Fran Laurie; Kathleen M McCarten; Janaki Moni; Richard S Pieters; Nancy Rosen; Kenneth Ulin; Marcia Urie; Allen R Chauvenet; Louis S Constine; James Deye; Bhadrasain Vikram; Debra Friedman; Robert B Marcus; Nancy P Mendenhall; Jon L Williams; James Purdy; Joel Saltz; Cindy L Schwartz; Keith S White; Suzanne Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-01 Impact factor: 7.038
Authors: C J Fabian; C M Mansfield; S Dahlberg; S E Jones; T P Miller; E Van Slyck; P N Grozea; F S Morrison; C A Coltman; R I Fisher Journal: Ann Intern Med Date: 1994-06-01 Impact factor: 25.391
Authors: Thomas J FitzGerald; Maryann Bishop-Jodoin; David S Followill; James Galvin; Michael V Knopp; Jeff M Michalski; Mark A Rosen; Jeffrey D Bradley; Lalitha K Shankar; Fran Laurie; M Giulia Cicchetti; Janaki Moni; C Norman Coleman; James A Deye; Jacek Capala; Bhadrasain Vikram Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-24 Impact factor: 7.038